- Home
- BON vs PLRZ Comparison
BON vs PLRZ Comparison
Compare BON & PLRZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- PLRZ
- Stock Information
- Founded
- BON 2006
- PLRZ 2005
- Country
- BON China
- PLRZ Israel
- Employees
- BON N/A
- PLRZ N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- PLRZ
- Sector
- BON Health Care
- PLRZ
- Exchange
- BON Nasdaq
- PLRZ NYSE
- Market Cap
- BON 6.6M
- PLRZ 5.9M
- IPO Year
- BON 2021
- PLRZ 2024
- Fundamental
- Price
- BON $1.12
- PLRZ $1.04
- Analyst Decision
- BON
- PLRZ
- Analyst Count
- BON 0
- PLRZ 0
- Target Price
- BON N/A
- PLRZ N/A
- AVG Volume (30 Days)
- BON 23.4K
- PLRZ 136.1K
- Earning Date
- BON 02-28-2025
- PLRZ 02-15-2025
- Dividend Yield
- BON N/A
- PLRZ N/A
- EPS Growth
- BON N/A
- PLRZ N/A
- EPS
- BON 0.17
- PLRZ N/A
- Revenue
- BON $23,844,556.00
- PLRZ N/A
- Revenue This Year
- BON $223.38
- PLRZ N/A
- Revenue Next Year
- BON $18.82
- PLRZ N/A
- P/E Ratio
- BON $6.42
- PLRZ N/A
- Revenue Growth
- BON N/A
- PLRZ N/A
- 52 Week Low
- BON $1.07
- PLRZ $0.77
- 52 Week High
- BON $5.31
- PLRZ $4.80
- Technical
- Relative Strength Index (RSI)
- BON 33.73
- PLRZ N/A
- Support Level
- BON $1.07
- PLRZ N/A
- Resistance Level
- BON $1.36
- PLRZ N/A
- Average True Range (ATR)
- BON 0.09
- PLRZ 0.00
- MACD
- BON -0.01
- PLRZ 0.00
- Stochastic Oscillator
- BON 18.28
- PLRZ 0.00
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from perfumes and fragrance products.
About PLRZ POLYRIZON LTD
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.